Member Info for roses

Indeed, her next scan is tomorrow and all indications are she is doing fantastic so we shouldn’t have long to wait for results

The share price is actually up from yesterdays close.

The share price closed at 24.5 yesterday but finished with a UT trade at 25.1 which was reported as the closing price, and then reverted back to the actual closing price when it opened this morning.

Chillpill, have the company published their priority list ?

Agreed, and going off all publicly available information the trial is going extremely well and assume we should have the next update in about 1 week or so.

Seems unbelievable to me that we are still only at the same price as a year ago after all this good news and a commercial deal and a raft of imminent updates.

Not sure about everyone else but I have been taking full advantage of the opportunity.

Indeed, 36p by the end of January.

I’ll take that as a minimum, although I suspect it may well be a lot higher than that.

I think it’s fair to say that the majority (if not all) posters on here are aware of and recognise the sensitive nature of the updates on the forum and to treat it as such.

The trial participant seems happy to share her experience and is obviously very thrilled with the results.

I agree that personal details such as names etc. Should not be used, however it is every investors duty and responsibility to research their shares as much as possible and to decree that verified publicly available trial participants insights should not be discussed or debated is not an option in todays world.

As long as everyone shows respect and as much tact as possible then there should be no issue in polite discussion and debate.

Hi chillpill

“We are encouraged that there were no safety concerns in Cohort 2, allowing us to proceed with the monotherapy expansion and into Cohort 3 in combination with checkpoint inhibitors, and look forward to announcing further safety and immunogenicity data in H2 2022."

Not long now until we get an update !

Always an extremely positive indicator.

If the results are that good and safety has been confirmed then they consider it inhumane to deny them the expanded dose.

“Next Covid-19 Strain May be More Dangerous, Lab Study Shows
Study was led by Alex Sigal in South African laboratory”

https://www.bloomberg.com/news/articles/2022-11-26/study-says-as-covid-evolves-in-long-term-infections-it-may-become-more-harmful?srnd=premium-europe&leadSource=uverify%20wall

Looking at the charts, the next major hurdle to break is 27.9p

With the expected news flow in the next 4 weeks it shouldn’t be too much of a hurdle !

Indeed, I must have searched ‘Modi’ at some stage. :)

Just seen an add on the right of this chat page for ‘Modibodi’

Did a double take and it’s an add for woman’s items!

Nothing ever goes up in a straight line. Needs time to consolidate around here before the next leg. And also gives time for 5he RSI to reset.

Very strong hold from me from here.

I wouldn’t bet against it !

Investopedia

“The relative strength indicator is not as reliable in trending markets as it is in trading ranges. In fact, most traders understand that the signals given by the RSI in strong upward or downward trends often can be false.”

As we know for years we have been in trading ranges.

We are now without a doubt in a trending market. As such the RSI is currently meaningless.

Hasiba, RSI is not at 92 it’s at 82

“It could go either way in the very short term”

Loving your conviction there.
Whichever way it goes, you’ll claim you’re right !

Scancell featuring in Zak mirs share talk yesterday “as the most encouraging stock he’s covering’. With a minimum of 23p

Indeed, the company is a completely different beast now than it was back then.

Very difficult and pointless to compare.